UCB Announces Plan to Seek Regulatory Approval for Fintepla in CDKL5 Deficiency Disorder Following Positive Phase 3 Results

UCB announced that it will move forward with regulatory submissions for Fintepla® (fenfluramine) as a treatment for seizures associated with CDKL5 Deficiency Disorder (CDD), following highly positive results from its Phase 3 clinical trial. This represents a potential third indication for Fintepla, which is already approved for Dravet syndrome and Lennox-Gastaut syndrome.

Gen Z Is Rewriting Office Culture

As Gen Z returns to the office in growing numbers, they’re not just filling the physical space — they’re transforming it. According to a CNBC article, this generation is leaning into authenticity, mental health, and digital fluency, bringing new energy to work environments older generations may no longer frequent. From candid check-ins on well-being, to dressing casually and speaking in their own voice, to fully embracing AI tools as collaborators — Gen Z is reshaping corporate norms on its own terms.

Smarter Pharmaceutical Warehousing Starts With Sharper Investments

Warehouse operations in the pharmaceutical sector are no longer background infrastructure. They’re active levers for efficiency, compliance, and product integrity. With regulatory pressures mounting and logistics complexity rising, warehouses have become critical control points, not just for inventory, but for reputation. That means companies can’t afford to treat upgrades as piecemeal patches. They need targeted investment in systems, design, people, and architecture. This article breaks down the most high-impact areas where pharmaceutical companies should be putting real money, not just attention.